These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 34706519)

  • 1. A five-year follow up study of stage I-IV of rectal cancer with an emphasis on epidermal growth factor over-expression.
    Kozłowska-Geller MA; Lewitowicz P; Głuszek SZ
    Pol J Pathol; 2021; 72(2):124-129. PubMed ID: 34706519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity.
    Kozłowska-Geller M; Głuszek S; Lewitowicz P
    Prz Gastroenterol; 2021; 16(4):330-338. PubMed ID: 34976241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis.
    Giralt J; de las Heras M; Cerezo L; Eraso A; Hermosilla E; Velez D; Lujan J; Espin E; Rosello J; Majó J; Benavente S; Armengol M; de Torres I;
    Radiother Oncol; 2005 Feb; 74(2):101-8. PubMed ID: 15816107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy.
    Giralt J; Eraso A; Armengol M; Rosselló J; Majó J; Ares C; Espin E; Benavente S; de Torres I
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1460-5. PubMed ID: 12459370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma.
    Dvorak J; Sitorova V; Ryska A; Sirak I; Richter I; Hatlova J; Ferko A; Melichar B; Petera J
    Strahlenther Onkol; 2012 Sep; 188(9):833-8. PubMed ID: 22847519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.
    Takahashi N; Yamada Y; Furuta K; Honma Y; Iwasa S; Takashima A; Kato K; Hamaguchi T; Shimada Y
    Br J Cancer; 2014 May; 110(11):2716-27. PubMed ID: 24800946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P21 is not a prognostic marker for rectal cancer - five-year follow up study of rectal cancer in stages I-IV.
    Kozłowska-Geller MA; Głuszek SZ; Lewitowicz P
    Contemp Oncol (Pozn); 2020; 24(4):247-251. PubMed ID: 33531872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
    Onn A; Correa AM; Gilcrease M; Isobe T; Massarelli E; Bucana CD; O'Reilly MS; Hong WK; Fidler IJ; Putnam JB; Herbst RS
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):136-43. PubMed ID: 14734462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.
    Nicholson S; Richard J; Sainsbury C; Halcrow P; Kelly P; Angus B; Wright C; Henry J; Farndon JR; Harris AL
    Br J Cancer; 1991 Jan; 63(1):146-50. PubMed ID: 1846551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
    Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
    J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of epidermal growth factor receptor and thymidylate synthase expression in primary liver cancer].
    Guo FY; Yang J; Xiong SM; Zhu MQ; Gao S; Li JP
    Zhonghua Gan Zang Bing Za Zhi; 2018 Sep; 26(9):666-669. PubMed ID: 30481863
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays.
    Yang XQ; Chen C; Peng CW; Hou JX; Liu SP; Qi CB; Gong YP; Zhu XB; Pang DW; Li Y
    Int J Nanomedicine; 2011; 6():2265-73. PubMed ID: 22072864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunohistochemical study on the expression of epidermal growth factor receptor (EGFR) in human colorectal carcinomas].
    Takemura K; Obara T; Okano S; Yokota K; Ura H; Saitoh Y; Koike Y; Okamura K; Namiki M
    Nihon Shokakibyo Gakkai Zasshi; 1991 May; 88(5):1177-83. PubMed ID: 1880949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer.
    Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
    Breast Cancer Res Treat; 2002 Jan; 71(1):67-75. PubMed ID: 11859875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.
    Neumann J; Wehweck L; Maatz S; Engel J; Kirchner T; Jung A
    Virchows Arch; 2013 Oct; 463(4):509-23. PubMed ID: 23934607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
    D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
    J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy.
    Zlobec I; Vuong T; Hayashi S; Haegert D; Tornillo L; Terracciano L; Lugli A; Jass J
    Br J Cancer; 2007 Mar; 96(5):793-800. PubMed ID: 17311026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
    Wu SG; Chang YL; Lin JW; Wu CT; Chen HY; Tsai MF; Lee YC; Yu CJ; Shih JY
    PLoS One; 2011; 6(8):e23303. PubMed ID: 21858063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.